---
title: "JPM: China's CDMO Sector Enters New Development Phase; Initiates Overweight on PHARMARON  and ASYMCHEM H Shrs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304591792.md"
description: "JPMorgan initiated coverage on PHARMARON and ASYMCHEM, assigning Overweight ratings to their H-shares and Neutral to A-shares. The bank views China's CDMO sector as entering a new development phase focused on commercialization. Forecasting EPS CAGR of 24% and 25% for PHARMARON and ASYMCHEM respectively from 2026-2030, JPM prefers H-shares due to better valuation upside compared to A-shares, which have already priced in recovery expectations."
datetime: "2026-11-06T07:03:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304591792.md)
  - [en](https://longbridge.com/en/news/304591792.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304591792.md)
generator: "portal-rs"
---

# JPM: China's CDMO Sector Enters New Development Phase; Initiates Overweight on PHARMARON  and ASYMCHEM H Shrs

JPMorgan published a research report stating that China's Contract Development and Manufacturing Organization (CDMO) sector is entering a new stage of development, with the next phase of growth depending more on whether suppliers can convert clients' advancing pipelines into sustainable commercialized production.

The bank expanded its coverage of China's CDMO stocks, initiating coverage on PHARMARON (03759.HK) -1.320 (-4.342%) Short selling $12.08M; Ratio 5.155% and PHARMARON (300759.SZ) -4.090 (-8.183%) A shares, as well as ASYMCHEM (002821.SZ) -6.420 (-3.976%) A shares and ASYMCHEM (06821.HK) -0.200 (-0.155%) Short selling $7.37M; Ratio 5.209% H shares. The bank forecast EPS CAGR for PHARMARON and ASYMCHEM at 24% and 25% respectively from 2026 to 2030, with faster earnings growth driven by economies of scale.

Among A and H shares, the bank prefers the H shares of PHARMARON and ASYMCHEM over their A shares. It assigned TP of HKD38 and HKD160 respectively for the H shares of PHARMARON and ASYMCHEM, both with initial Overweight ratings. Their respective A share TPs were set at RMB50 and RMB170, with initial Neutral ratings, as A-share valuations have already reflected recovery expectations, leaving less room should capacity growth slow down.

### Related Stocks

- [03759.HK](https://longbridge.com/en/quote/03759.HK.md)
- [06821.HK](https://longbridge.com/en/quote/06821.HK.md)
- [002821.CN](https://longbridge.com/en/quote/002821.CN.md)
- [300759.CN](https://longbridge.com/en/quote/300759.CN.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)

## Related News & Research

- [Asymchem Laboratories Tianjin Discloses Share Repurchase in HKEX Next Day Return](https://longbridge.com/en/news/306246115.md)
- [G Sachs: Strong 3Q Orders for China's CRO and CDMO Firms Enhance Visibility for 2027](https://longbridge.com/en/news/305267293.md)
- [Pharmaron Beijing Co., Ltd. Class H (17Q1) was downgraded to a Hold Rating at UBS](https://longbridge.com/en/news/296967052.md)
- [Pharmaron Renews Three-Year Research Services Agreement With Newbay Technology](https://longbridge.com/en/news/303219721.md)
- [Asymchem Shareholders Approve Amendments to Articles at 2026 EGM](https://longbridge.com/en/news/302417622.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**